These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 15998421

  • 21. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy.
    Sharzehi K, Huang MA, Schreibman IR, Brown KA.
    Can J Gastroenterol; 2010 Oct; 24(10):588-92. PubMed ID: 21037986
    [Abstract] [Full Text] [Related]

  • 22. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
    Herrero JI, Quiroga J, Sangro B, Girala M, Gómez-Manero N, Pardo F, Alvárez-Cienfuegos J, Prieto J.
    Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843
    [Abstract] [Full Text] [Related]

  • 23. A comparison of a standard-dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study.
    Li X, Tian J, Wu J, He Q, Li H, Han F, Li Q, Chen Y, Ni Q, Chen J.
    Clin Ther; 2009 Apr; 31(4):741-50. PubMed ID: 19446147
    [Abstract] [Full Text] [Related]

  • 24. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine.
    Richardson PD, James PD, Ryder SD.
    J Hepatol; 2000 Sep; 33(3):371-5. PubMed ID: 11019991
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis.
    Zachou K, Gatselis NK, Arvaniti P, Gabeta S, Rigopoulou EI, Koukoulis GK, Dalekos GN.
    Aliment Pharmacol Ther; 2016 May; 43(10):1035-47. PubMed ID: 26991238
    [Abstract] [Full Text] [Related]

  • 29. Mycophenolate mofetil as second line therapy in autoimmune hepatitis?
    Hennes EM, Oo YH, Schramm C, Denzer U, Buggisch P, Wiegard C, Kanzler S, Schuchmann M, Boecher W, Galle PR, Adams DH, Lohse AW.
    Am J Gastroenterol; 2008 Dec; 103(12):3063-70. PubMed ID: 18853972
    [Abstract] [Full Text] [Related]

  • 30. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation.
    Schuller S, Wiederkehr JC, Coelho-Lemos IM, Avilla SG, Schultz C.
    Transplant Proc; 2005 Mar; 37(2):1151-2. PubMed ID: 15848653
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Clinical outcome of heart transplant recipients receiving tacrolimus with or without mycophenolate mofetil.
    Fuchs U, Tenderich G, Zittermann A, Szabados F, Minami K, Koerfer R.
    Clin Transplant; 2006 Mar; 20(4):450-6. PubMed ID: 16842520
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience.
    Mastrobuoni S, Ubilla M, Cordero A, Herreros J, Rabago G.
    Transplant Proc; 2007 Sep; 39(7):2163-6. PubMed ID: 17889125
    [Abstract] [Full Text] [Related]

  • 35. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients.
    Włodarczyk Z, Wałaszewski J, Perner F, Vitko S, Ostrowski M, Bachleda P, Kokot F, Klinger M, Szenohradsky P, Studenik P, Navratil P, Asztalos L, Rutkowski B, Nagy KK, Hickey D.
    Ann Transplant; 2002 Sep; 7(3):28-31. PubMed ID: 12465429
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of mycophenolate mofetil and tacrolimus combination therapy in patients with lupus nephritis: a nationwide multicentre study.
    Park DJ, Kang JH, Lee KE, Bae SC, Chung WT, Choe JY, Jung SY, Kim YS, Lee HS, Lee J, Lee YA, Park SH, Park YJ, Suh CH, Yoo DH, Lee SS.
    Clin Exp Rheumatol; 2019 Sep; 37(1):89-96. PubMed ID: 29998829
    [Abstract] [Full Text] [Related]

  • 37. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab.
    Ojogho O, Sahney S, Cutler D, Baron PW, Abdelhalim FM, James S, Zuppan C, Franco E, Concepcion W.
    Pediatr Transplant; 2005 Feb; 9(1):80-3. PubMed ID: 15667617
    [Abstract] [Full Text] [Related]

  • 38. A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment.
    De Lemos-Bonotto M, Valle-Tovo C, Costabeber AM, Mattos AA, Azeredo-da-Silva ALF.
    Eur J Gastroenterol Hepatol; 2018 Feb; 30(2):212-216. PubMed ID: 29227329
    [Abstract] [Full Text] [Related]

  • 39. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW.
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [Abstract] [Full Text] [Related]

  • 40. Mycophenolate mofetil severely depresses antibody response to CMV infection in early posttransplant period.
    Zmonarski SC, Boratynska M, Madziarska K, Klinger M, Kusztel M, Patrzalek D, Szyber P.
    Transplant Proc; 2003 Sep; 35(6):2205-6. PubMed ID: 14529889
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.